3,495 reports of this reaction
4.7% of all BOTULINUM TOXIN TYPE A reports
#2 most reported adverse reaction
DRUG INEFFECTIVE is the #2 most commonly reported adverse reaction for BOTULINUM TOXIN TYPE A, manufactured by Galderma Laboratories, L.P.. There are 3,495 FDA adverse event reports linking BOTULINUM TOXIN TYPE A to DRUG INEFFECTIVE. This represents approximately 4.7% of all 74,480 adverse event reports for this drug.
Patients taking BOTULINUM TOXIN TYPE A who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is moderately reported among BOTULINUM TOXIN TYPE A users, representing a notable but not dominant share of adverse events.
In addition to drug ineffective, the following adverse reactions have been reported for BOTULINUM TOXIN TYPE A:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 3,495 FDA reports for BOTULINUM TOXIN TYPE A. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 4.7% of all adverse event reports for BOTULINUM TOXIN TYPE A, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking BOTULINUM TOXIN TYPE A, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.